TRH mimetics have been shown to be useful in the treatment of spinocerebellar degeneration (Shimizu et al., 2020; Ijiro et al., 2022), amyotrophic lateral sclerosis (Hawley et al., 1987), spinal muscular atrophy (Kat o et al., 2009), prolonged disturbance of consciousness due to aneurysmal subarachnoid hemorrhage (Shibata et al., 2019), Parkinson’s disease (Zheng et al., 2018a; Zheng et al., 2018b), epilepsy (Rajput et al., 2009; Sah et al., 2011), psychiatric disorders with underlying inflammatory processes (Kamath, 2012), and possibly depression (Duval et al., 2021). This evidence concerns the gene TRH and Parkinson disease.